Introduction: Various biomarkers are used to evaluate the severity and prognosis of community acquired pneumonia (CAP). Objectives: To study and compare the prognostic value of MR-proADM, РСТ and CRP in predicting the severity and outcome of CAP. Methods: A prospective cohort study of 92 patients hospitalized with CAP in the Clinic of Pneumology and Phthisiatrics of MHAT "Saint Marina"-Varna in 2015 was conducted. The biomarkers were measured on admission. Midregional proadrenomedullin (MR-proADM) and procalcitonin (РСТ) were measured by standard ELISA, and C-reactive protein (CRP) was determined by latex-enhanced immunoturbidimetric assay. CAP severity was assessed by CURB-65. Results: Patients were on average 59.2±16.8 years of age; 68.5% of them were male. The in-hospital mortality rate was 7.6%. The three biomarkers MR-proADM, РСТ and CRP were significantly higher in non-survivors compared to survivors (0.918±0.045 ng/ml vs. 0.397±0.269ng/ml, р<0.001; 2.14±0.60ng/ml vs. 1.12±0.68ng/ml, р<0.001 and 215.12±96.39 mg/L vs.175.74±221.5mg/L, p<0.05 respectively). In patients who needed intensive care, the biomarkers were also significantly higher than those in patients treated in the general hospital unit (0.509±0.336ng/ml vs. 0.414±0.28ng/ml, р<0.05; 1.92±0.76 ng/ml vs. 1.15±0.70ng/ml, p<0.05 and 221.98±100.34 mg/L vs. 165.31±122.84 mg/L, p<0.05 resp.). MR-proADM and РСТ showed a moderate correlation with the CURB-65 (r=0.33, p<0.01 and r=0.30, p<0.05 respectively). CRP did not correlate with the CURB-65 (r=0.10, p>0.05). Conclusion: MR-proADM, РСТ and CRP were significantly higher in non-survivors and in patients treated in the intensive care unit. MR-proADM and РСТ showed a moderate correlation with the CURB-65, while the correlation coefficient for MR-proADM was higher. CRP did not correlate with the CURB-65.
Introduction
Various biomarkers are in use for evaluation of the severity and prognosis of community acquired pneumonia (CAP). Some of them, such as C-reactive protein (CRP) and, in some hospitals procalcitonin (PCT), are used routinely in clinical practice, but others, such as pro-adrenomedullin have been recently studied in an attempt to find better prognostic tools in CAP. CRP was discovered in 1930 by Tillet and Francis. It is an acute-phase protein, which is an early and sensitive, but nonspecific marker of systemic inflammation. It is synthesized mainly by hepatocytes under the influence of IL-6, IL-1 and TNF (Clyne et al., 1999) . Apart from its increase during infection, its level is also increased in autoimmune diseases, trauma, tissue necrosis and malignancy. РСТ is the precursor of the active hormone calcitonin. It belongs to CALC-1gene family. It was discovered in 1975 by Moya. Its levels begin to rise within 2 hours after bacterial infection which makes it earlier marker than CRP. It reaches a peak-concentration at 12 hours and has a half-life of 24 hours (Meisner 2000) . Interferon gamma, which is produced in response to viral infection, blocks PCT synthesis. Therefore, its levels do not rise in viral infections. These reasons make it a reliable marker for the etiological distinction between viral and bacterial infections and for the need of antibiotic treatment. Therefore, it would be aminoacids, mainly produced by cardiovascular tissue, but also by the adrenal medulla, lungs, kidneys, neurons. It is one of the most potent endogenous vasodilators. Its levels rise in the syndrome of systemic inflammatory response due not only to infections, but also to burns, trauma, traumatic shock, pancreatitis (Ueda et al., 1999) . Its direct measurement is difficult because of its short half-life (22 minutes), due to binding to plasma proteins and technical difficulties. For practical purposes a part of the molecule of its precursor known as midregional pro-adrenomedulin (MR-proADM) is used. It has no biologically active properties, but according to its levels, the levels of adrenomeddullin can be judged. In healthy individuals, the typical values of MR-proADМ are 0.10-0.64nmol/L without difference between the sexes (Morgenthaler et al., 2005) .
Objectives
To study and compare the prognostic value of MR-proADM, РСТ and CRP in predicting the severity and outcome of CAP. Methods A prospective cohort study of 92 patients hospitalized in the Clinic of Pneumology and Phthisiatrics of MHAT "Saint Marina"-Varna in 2015 was conducted. The biomarkers were measured on admission. MR-proADM and РСТ were measured by standard ELISA, and CRP was determined by latexenhanced immunoturbidimetric assay. CAP severity was assessed by CURB-65. Data were analyzed with SPSSv20.0. We used comparative and correlation analyses. Quantitative variables were reported as mean values and standard deviation (mean ± SD), and the qualitative variables were presented in number and relative proportion (%).
Results
The patients were on average 59.2±16.8 years of age; 63 (68.5%) of them were male and 29 (31.5%) were female. 22 patients (23.9%) were treated in the intensive care unit (ICU). 7 patients (7.6%) died during hospital stay. Characteristics of the group and the mean values of the three biomarkers are shown in Table 1 . We compared the levels of the three biomarkers in non-survivors and survivors and found out that they were significantly higher in deceased patients. MR-proADM in non-survivors was 0.918±0.045 ng/ml versus 0.397±0.269ng/ml in survivors, р<0.001. РСТ in non-survivors was 2.14±0.60ng/ml versus 1.12±0.68 ng/ml in survivors, р<0.001, and CRP was 215.12±96.39 mg/L in non-survivors versus 175.74±221.5mg/L in survivors, p<0.05). Figure 1 a, b and c In the patients who needed intensive care, the three biomarkers were also significantly higher compared to those of the patients treated in the general hospital unit. MR-proADM in the patients treated in ICU was 0.509±0.336 ng/ml versus 0.414±0.28 ng/ml in the patients of the general hospital unit, р<0.05. РСТ in the patients treated in ICU was 1.92±0.76 ng/ml vs. We examined the mean values of the three biomarkers in the severity groups according to CURB-65 and established that MR-proADM and РСТ increased significantly with the increase of the severity of CAP. No elevation of CRP was found with the increase of the severity of CAP, assessed by the CURB-65 (see Figure 2 a, b and c). We also established that MR-proADM and РСТ showed a moderate correlation with the CURB-65 score (r=0.33, p<0.01 and r=0.30, p<0.05 respectively). CRP did not correlate with the CURB-65 score (r=0.10, p>0.05). 
Discussion
Our study found that the levels of the three biomarkers were higher in deceased patients compared to survivors. Other authors also reported higher levels of MR-proADM in non-survivors Huang et al., 2009; Suberviola et al., 2012) . Higher levels of CRP and РСТ in non-survivors were reported in many publications as well (Chalmers et al., 2008; Krüger et al., 2010; Menéndez et al., 2009) . We think that these higher levels of the biomarkers may be linked with the more severe systemic inflammatory response of the deceased patients. We also found significantly higher values of the three biomarkers in the ICU patients. Other authors have also established the ability of MR-proADM to predict the need of intensive care. Renaud et al., for example, found significantly higher values of MR-proADM in patients with severe early pneumonia (Renaud et al., 2012) . РСТ is also able to predict the need for intensive care (Ramírez et al., 2011) . Therefore, we consider that biomarkers can be used not only as mortality predictors, but also as predictors for the need of intensive care. Our study showed an increase in MR-proADM and РСТ in high-risk groups according to CURB-65. Our data are consistent with the results of other authors, who have also observed such an increase in high-risk groups Lacoma et al., 2014) . Huang et al. established that elevated MR-proADM levels correlate with increased severity of CAP assessed by PSI (Huang et al. 2009 ), and Krüger, established that РСТ levels increased with the severity of CAP assessed by the modified CRB-65 score, while there was no such increase in CRP (Krüger et al., 2008) . We also did not find the elevation of CRP associated with the increase of the severity of pneumonia, as CRP did not correlate with the CURB-65 score. Therefore, we regard the other two biomarkers as better predictors of pneumonia severity compared with CRP. We found a moderate correlation of MR-proADM and РСТ with CURB-65. Some authors have found better coefficients of the severity scores, for example, Bello established the correlation coefficient of MR-proADM with CURB-65 to be r=0.561 (Bello et al., 2012) . We believe that the lower correlation coefficients established by us are most likely due to the relatively small number of studied patients, most of which fell into the low-risk groups according to CURB-65. This may be considered a limitation of the study. A number of authors have established a superior prognostic accuracy of MR-proADM compared with РСТ . In our study, we have also found a slightly better correlation coefficient of MR-proADM with CURB-65 compared to that of РСТ, as both markers showed moderate correlation with the severity. Conclusion MR-proADM, РСТ and CRP were significantly higher in non-survivors and ICU patients. MR-proADM and РСТ showed a moderate correlation with the CURB-65, as the correlation coefficient for MR-proADM was higher. CRP did not correlate with the CURB-65. Biomarkers provide fast and reliable information to physicians about the severity and prognosis of pneumonia and can help them to take correct treatment decisions. They should therefore be included in the risk stratification of patients with CAP as predictors of severity and poor outcome.
